Solvay went into this earnings print as a heavily discounted stock, with the share price at €26.56 and flagged as trading far below an estimated fair value. The market has treated it as a structurally challenged chemicals group with high debt and a stretched dividend, so every quarter now serves as a credibility check on the turnaround story.
The headline this time is profit quality. Quarterly basic earnings per share moved to €0.60 on net income of €63m, yet trailing twelve month figures still show a loss and negative earnings from continuing operations. For you as an investor, this is less about one quarter’s rebound and more about whether the balance sheet and cash flows can sustain the promised reset.
Like the turnaround story at Solvay but worried about loss making trailing earnings and balance sheet risk? Take a look at our screener of stocks that pair discounted valuations with stronger fundamentals in the list of solid balance sheet and fundamentals stocks (414 results).
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs. Q2 2025): €1,031 million vs. €1,212 million (decline of 14.9%)
- Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): €63 million vs. €9 million (increase of 600%)
- Basic EPS (Q2 2026 vs. Q2 2025): €0.60 vs. €0.09 (increase of 596.4%)
- Trailing Twelve Month Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): loss of €27 million vs. profit of €139 million (reversal from profit to loss)
Prefer clear visuals over scrolling through paragraphs of earnings detail and raw figures? See Solvay’s full financial picture at a glance, including how the balance sheet and debt profile fit together, in the interactive company report for Solvay.
Solvay bull case hinges on cost and mix progress
Bulls argue Solvay can reset profitability through cost savings, higher value products and energy transition projects, making earnings more resilient. Q2 gives some support. Underlying EBITDA of €187m and an 18.1% margin came despite weaker soda ash and a Middle East outage, helped by €26m of operational savings that show the cost program is delivering cash, not just targets. Management is still funding about €90m of transformation spend in 2026 and has reaffirmed full year EBITDA of €770 to €850m and free cash flow above €200m. That suggests internal confidence that savings and the planned Q3 restart of the Saudi peroxide plant can offset softer markets. Growth in electronic grade peroxide for semiconductors and fresh capex at La Rochelle for rare earth separation point to real capital being committed to the higher margin mix that underpins the long term bullish story.
Bear case focuses on soda ash strain and cash
Bears see Solvay as a cyclical chemicals group with structural soda ash pressure, execution risk on transformation and a stretched balance sheet. Parts of Q2 fit that concern. Underlying sales were just above €1b and down 7% organically, with Basic Chemicals hit by significant seaborne soda ash price pressure that hurts export margins. Group EBITDA fell 20% year on year and trailing twelve month earnings from continuing operations remain loss making, which challenges the idea of a clean profit reset. Free cash flow to shareholders was €15m in H1 and €11m outflow in Q2 once working capital and €106m of restructuring cash are included. Net debt of €1.8b and leverage temporarily above 2x show limited room for large missteps, even if the BBB minus rating is intact. Guidance now leans heavily on a timely Saudi restart and no further soda ash deterioration.
After EBITDA pressure, loss making trailing earnings and a dividend not covered by profit, it is fair to ask whether Solvay’s challenges run deeper. Review the independent risk analysis for Solvay which shows 2 important warning signsStay Ahead With Simply Wall St
If Solvay’s discounted share price and mixed earnings picture have caught your eye, register for free with Simply Wall St and add it to a Watchlist to track price against fair value estimates and watch how the turnaround story progresses. When you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on key updates that matter to your holdings. For a longer term view, tap into the Community to see how other investors are thinking about the same risks and potential catalysts. This combination can help you surface hidden drivers and red flags earlier so you stay ahead of the market.
Seeking Alternatives Beyond Solvay Today
Markets can change quickly, and potential breakout stocks may gain momentum before many investors notice. Explore new ideas that may currently be under the radar and consider them promptly.
- Identify potential leaders early by scanning curated companies with healthy balance sheets in the list of solid balance sheet and fundamentals stocks (414 results).
- Focus on emerging profit momentum by reviewing curated 69 profitable AI stocks that aren't just burning cash that already generate earnings and disciplined cash flow.
- Review hand picked 35 power grid technology and infrastructure stocks that could be positioned to participate if grid upgrades remain a priority for policymakers and utilities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com